Literature DB >> 10653879

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

J S Smith1, A Perry, T J Borell, H K Lee, J O'Fallon, S M Hosek, D Kimmel, A Yates, P C Burger, B W Scheithauer, R B Jenkins.   

Abstract

PURPOSE: A recent report suggests that alterations of chromosome arms 1p and 19q are associated with chemotherapeutic response and overall survival in anaplastic oligodendroglioma patients treated with procarbazine, lomustine, and vincristine chemotherapy. We set out to further clarify the diagnostic and prognostic implications of these alterations in a broader set of diffuse gliomas, including astrocytic neoplasms and low-grade oligodendrogliomas. PATIENTS AND METHODS: Fluorescence in situ hybridization (FISH) signals from DNA probes mapping to 1p and 19q common deletion regions were enumerated in 162 diffuse gliomas (79 astrocytomas, 52 oligodendrogliomas, and 31 mixed oligoastrocytomas), collected as part of an ongoing prospective investigation of CNS tumors.
RESULTS: The oligodendroglial phenotype was highly associated with loss of 1p (P =.0002), loss of 19q (P <.0001), and combined loss of 1p and 19q (P <.0001). Combined loss of 1p and 19q was identified as a univariate predictor of prolonged overall survival among patients with pure oligodendroglioma (log-rank, P =.03) and remained a significant predictor after adjusting for the effects of patient age and tumor grade (P <.01). This favorable association was not evident in patients with astrocytoma or mixed oligoastrocytoma.
CONCLUSION: Combined loss of 1p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade. Given the lack of this association in patients with astrocytic neoplasms and the previously demonstrated chemosensitivity of oligodendrogliomas, a combined approach of histologic and genotypic assessment could potentially improve existing strategies for patient stratification and management.

Entities:  

Mesh:

Year:  2000        PMID: 10653879     DOI: 10.1200/JCO.2000.18.3.636

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  216 in total

Review 1.  Glioma classification: a molecular reappraisal.

Authors:  D N Louis; E C Holland; J G Cairncross
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Molecular profile of oligodendrogliomas in young patients.

Authors:  Vaishali Suri; Prerana Jha; Shipra Agarwal; Pankaj Pathak; Mehar Chand Sharma; Vikas Sharma; Sudhanshu Shukla; Kumaravel Somasundaram; Ashok Kumar Mahapatra; Shashank Sharad Kale; Chitra Sarkar
Journal:  Neuro Oncol       Date:  2011-10       Impact factor: 12.300

3.  Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics.

Authors:  Mahfoud Assem; Zita Sibenaller; Supreet Agarwal; Maha S Al-Keilani; Mohammad A Y Alqudah; Timothy C Ryken
Journal:  OMICS       Date:  2012-03

4.  Extradural cord compression due to metastatic oligodendroglioma.

Authors:  Jeff Garner; Yehya Morcos; Mohammed Bari
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

5.  Oligodendrogliomas: a short history of clinical developments.

Authors:  Martin J van den Bent
Journal:  CNS Oncol       Date:  2015

6.  1p/19q-driven prognostic molecular classification for high-grade oligodendroglial tumors.

Authors:  Haihui Jiang; Zhe Zhang; Xiaohui Ren; Wei Zeng; Wenqing Jia; Junmei Wang; Song Lin
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

Review 7.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

8.  Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth.

Authors:  Chibo Hong; K Scott Moorefield; Peter Jun; Kenneth D Aldape; Samir Kharbanda; Heidi S Phillips; Joseph F Costello
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

9.  High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.

Authors:  Lauren E Abrey; Barrett H Childs; Nina Paleologos; Lynne Kaminer; Steven Rosenfeld; Donna Salzman; Jonathan L Finlay; Sharon Gardner; Kendra Peterson; Wendy Hu; Lode Swinnen; Robert Bayer; Peter Forsyth; Douglas Stewart; Anne M Smith; David R Macdonald; Susan Weaver; David A Ramsey; Stephen D Nimer; Lisa M DeAngelis; J Gregory Cairncross
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

10.  BCNU down-regulates anti-apoptotic proteins bcl-xL and Bcl-2 in association with cell death in oligodendroglioma-derived cells.

Authors:  Richard A Lytle; Zhihong Jiang; Xiao Zheng; Keith M Rich
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.